Core Insights - GoodRx Holdings, Inc. (GDRX) reported revenue of $203.07 million for the quarter ended June 2025, reflecting a 1.2% increase year-over-year, while EPS was $0.09, up from $0.08 in the same quarter last year [1] - The reported revenue fell short of the Zacks Consensus Estimate of $205.18 million, resulting in a surprise of -1.03%, and the EPS also missed the consensus estimate of $0.10 by 10% [1] Financial Performance Metrics - Monthly Active Consumers stood at 6, matching the average estimate from three analysts [4] - Subscription plans totaled 668, slightly below the two-analyst average estimate of 677 [4] - Revenue from prescription transactions was $143.06 million, which was lower than the estimated $148.77 million, marking a -2.5% change year-over-year [4] - Revenue from other sources was $4.56 million, compared to the average estimate of $4.63 million, representing a -15.5% year-over-year change [4] - Revenue from pharma manufacturer solutions reached $34.98 million, exceeding the average estimate of $31.54 million, showing a +32% year-over-year increase [4] - Subscription revenue was reported at $20.46 million, below the estimated $20.93 million, reflecting a -7% change compared to the previous year [4] Stock Performance - GoodRx shares have declined by -9.3% over the past month, contrasting with a +0.5% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]